发明公开
EP2231165A4 METHOD OF DETERMINING THE PROBABILITY OF A THERAPEUTIC RESPONSE IN CANCER CHEMOTHERAPY WITH CARDIAC GLYCOSIDE
有权
确定用Herzglylycoside治疗癌症化疗的治疗反应概率的方法
- 专利标题: METHOD OF DETERMINING THE PROBABILITY OF A THERAPEUTIC RESPONSE IN CANCER CHEMOTHERAPY WITH CARDIAC GLYCOSIDE
- 专利标题(中): 确定用Herzglylycoside治疗癌症化疗的治疗反应概率的方法
-
申请号: EP08850574申请日: 2008-11-06
-
公开(公告)号: EP2231165A4公开(公告)日: 2010-12-15
- 发明人: NEWMAN ROBERT A , YANG PEIYING , ADDINGTON O CRANDELL
- 申请人: PHOENIX BIOTECHNOLOGY INC
- 专利权人: PHOENIX BIOTECHNOLOGY INC
- 当前专利权人: PHOENIX BIOTECHNOLOGY INC
- 优先权: US98750107 2007-11-13
- 主分类号: G01N33/574
- IPC分类号: G01N33/574 ; A61K31/58 ; A61K31/704 ; A61K36/24 ; G01N33/564
摘要:
A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.
信息查询
IPC分类: